国药现代：子公司获布美他尼注射液药品注册证书

Core Viewpoint - The company has received approval for the registration of Bumetanide injection from the National Medical Products Administration, which indicates a significant advancement in its product offerings [1] Group 1 - The full subsidiary of the company, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., is responsible for the newly approved Bumetanide injection [1] - Bumetanide injection is primarily indicated for the treatment of edema-related diseases, hypertension, and the prevention of acute renal failure [1]